论文信息 - Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma. - 字舞流文

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

J. Fagerberg | R. Advani | M. Beylot-Barry | U. Hillen | M. Duvic | A. Lerner | B. Pohlman | O. Shpilberg | D. Ben‐Yehuda | F. Foss | K. Hymes | T. Intragumtornchai | A. Lekhakula | M. Beylot‐Barry | D. Ben-yehuda